Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia

Combariza, Juan Felipe; Arango, Myrtha; Díaz, L.; Agudelo, Claudia; Hernandez, Sonia Parrilla; Madera, Ana María; León, Guillermo; Avila, Vladimir; Bautista, Leonardo; Valdés, Jaime; Orduz, Rocío; Mejía, Fabián Andrés; Moreno, Liliana; Ramírez, Carlos Alberto García

doi:10.1016/j.clml.2020.11.010

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is the first BsAbs drug approved by the FDA to treat leukemia cells through human T cells. Patients with ALL who are cured always have some measurable residual disease (MRD), which often causes a relapse (180,181). After blinatumomab treatment, a certain degree of complete remission (CR) can be achieved (182)(183)(184).…”

Section: Blinatumomabmentioning

confidence: 99%

Bispecific Antibodies: From Research to Clinical Application

Tang³

et al. 2021

Front. Immunol.

185

131

View full text Add to dashboard Cite

Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different antigens or two different epitopes on the same antigen. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy as well as for the treatment of other diseases. Recently, with progress in antibody or protein engineering and recombinant DNA technology, various platforms for generating different types of BsAbs based on novel strategies, for various uses, have been established. More than 30 mature commercial technology platforms have been used to create and develop BsAbs based on the heterologous recombination of heavy chains and matching of light chains. The detailed mechanisms of clinical/therapeutic action have been demonstrated with these different types of BsAbs. Three kinds of BsAbs have received market approval, and more than 110 types of BsAbs are at various stages of clinical trials. In this paper, we elaborate on the classic platforms, mechanisms, and applications of BsAbs. We hope that this review can stimulate new ideas for the development of BsAbs and improve current clinical strategies.

show abstract

Section: Blinatumomabmentioning

confidence: 99%

Bispecific Antibodies: From Research to Clinical Application

Tang³

et al. 2021

Front. Immunol.

185

131

View full text Add to dashboard Cite

show abstract

A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation

Xiao,

Zhou,

Zhu

et al. 2024

Bone Marrow Transplant

View full text Add to dashboard Cite

Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America

Basquiera

Seiwald

Aguilera

et al. 2023

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols. METHODS The Americas Health Foundation organized a panel of hematologists from Argentina, Brazil, Chile, Colombia, and Mexico to examine ALL diagnosis and therapy and produce recommendations. RESULTS Lack of regional data, unequal access to diagnosis and therapy, inadequate treatment response, and uneven health care distribution complicate adult ALL management. The panel recommended diagnosis, first-line and refractory treatment, and post-transplantation maintenance. Targeted treatments, including rituximab, blinatumomab, and inotuzumab ozogamicin, are becoming available in LA and must be equitably accessed. CONCLUSION This review adapts global information on treating ALL to LA. Governments, the medical community, society, academia, industry, and patient advocates must work together to improve policies.

show abstract

Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia

Cited by 3 publications

References 25 publications

Bispecific Antibodies: From Research to Clinical Application

Bispecific Antibodies: From Research to Clinical Application

A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation

Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America

Contact Info

Product

Resources

About